AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16180593
Drug: Usual arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual arm therapy of a similar duration and frequency to the experimental treatment
Trial: 12966125
Drug: Shiga toxin-binding
RxNorm normalized name: tetanus toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shiga toxin-binding agent (500 mg/kg daily for 7 days)
Trial: 9001924
Drug: Tepoxalin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 25 mg
Trial: 9001924
Drug: Tepoxalin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 100 mg
Trial: 9001924
Drug: Tepoxalin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 200 mg
Trial: 9001924
Drug: Tepoxalin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 400 mg
Trial: 9001924
Drug: Tepoxalin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 800 mg
Trial: 9001924
Drug: Tepoxalin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tepoxalin 400 mg (multiple dose)
Trial: 30869642
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) - face-to-face CBT
Trial: 27347792
Drug: Individual reminiscence
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual reminiscence sessions (5 weekly sessions)
Trial: 22409644
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 10 weeks, supplemented with up to 4 caregiver educational sessions.
Trial: 15956632
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg, 3 times daily for 1 year)
Trial: 15956632
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 times daily for 1 year)
Trial: 10579613
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg depot once every 28 days for four months, followed by additional cycles if menorrhagia occurred)
Trial: 1931534
Drug: Bioavail slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioavail slow-release theophylline capsule
Trial: 24289920
Drug: Eculizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24; or 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24)
Trial: 22344966
Drug: Vitamin D3-fortified
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-fortified doogh (FD; 500 IU/250 mL, n=50)
Trial: 22344966
Drug: Plain doogh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain doogh (PD; no detectable vitamin D/250 mL, n=50)
Trial: 19568826
Drug: Atomoxetine (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.4 mg/kg mean final dose)
Trial: 15970067
Drug: Doxazosin (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1-8 mg)
Trial: 15970067
Drug: Bendrofluazide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (2.5 mg)
Trial: 8880057
Drug: Orlistat 50
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orlistat 50 mg 3 times daily for 7 or 8 days
Trial: 6150771
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus saline
Trial: 6150771
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus cimetidine
Trial: 6150771
Drug: Insulin plus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin plus dextrose
Trial: 24195949
Drug: Intrathecal SP‐SAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal SP‐SAP (20‐60 ?g) in addition to standard‐of‐care analgesic therapy
Trial: 24195949
Drug: Standard‐of‐care analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard‐of‐care analgesic therapy alone (control)
Trial: 21626017
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (GaAlAs, 640 nm, 4 J/cm(2), 0.10 W, 70 s)
Trial: 21626017
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (InGaAlP, 660 nm, 4 J/cm(2), 0.03 W, 25 s)
Trial: 18633599
Drug: Polidocanol 5
RxNorm normalized name: polidocanol 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol 5 mg/ml (group A)
Trial: 18633599
Drug: Polidocanol 10
RxNorm normalized name: polidocanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol 10 mg/ml (group B)
Trial: 18633599
Drug: Polidocanol 10
RxNorm normalized name: polidocanol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol 10 mg/ml (additional treatment for unsatisfied patients)
Trial: 9038459
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg intravenously
Trial: 16418023
Drug: Meperidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.4 mg/kg intravenously
Trial: 9126713
Drug: Cognitive-existential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-existential group therapy integrated over 6 months with adjuvant chemotherapy.
Trial: 9126713
Drug: Cognitive-existential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-existential group therapy
Trial: 2876741
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion (250 micrograms/h continuously during 120 h)
Trial: 2876741
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg IV every 4 h for 5 days) and pirenzepine (10 mg IV every 8 h for 5 days)
Trial: 31602530
Drug: Thresholds for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thresholds for diagnosing IT success at 6 months post-transplant: SD at 22.76 mg/dL (sensitivity 88.89%, specificity 80.00%); CV at 17.47% (sensitivity 88.89%, specificity 70.00%); MAGE at 54.81 mg/dL (sensitivity 88.89%, specificity 80.00%); GVP at 12.27% (sensitivity 88.89%, specificity 70.00%).
Trial: 29422651
Drug: Dual-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 75g carbohydrate meal
Trial: 29422651
Drug: Dual-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach for 45g carbohydrate meal
Trial: 29422651
Drug: Overestimated meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overestimated meal insulin bolus for 75g carbohydrate meal
Trial: 29422651
Drug: Overestimated meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overestimated meal insulin bolus for 45g carbohydrate meal
Trial: 29422651
Drug: Dual-hormone closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-hormone closed-loop system (DH-CLS) with simplified meal bolus approach
Trial: 18690349
Drug: Antithrombin (AT)
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin gamma (DB16094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin (AT) administration for four consecutive days after thermal injury
Trial: 18690349
Drug: Non-antithrombin (non-AT)
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-antithrombin (non-AT) treatment
Trial: 15978306
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus HCTZ 12.5 mg OD
Trial: 15978306
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus HCTZ 25 mg OD
Trial: 15978306
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg OD
Trial: 8992964
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg paracetamol suppository
Trial: 8992964
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg paracetamol suppository
Trial: 8992964
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cut-in-half paracetamol tablet
Trial: 6104935
Drug: Lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.5 mg orally at 2200 h and 0800 h
Trial: 6104935
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg orally at the same times
Trial: 6104935
Drug: Lorazepam 2.5
RxNorm normalized name: lorazepam 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2.5 mg orally
Trial: 7034755
Drug: Diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 10 mg orally
Trial: 15497662
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Kolestor)
Trial: 9481974
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam intravenously
Trial: 2188410
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam rectally
Trial: 9481974
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg diazepam rectally
Trial: 30184543
Drug: Biweekly cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biweekly cetuximab (500 mg/m2)
Trial: 30184543
Drug: Weekly cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly cetuximab (250 mg/m2)
Trial: 22809163
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol (TP)
Trial: 22276821
Drug: Docetaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (100 mg/m² on day 1)
Trial: 22276821
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² on day 1) + Capecitabine (825 mg/m² twice a day on days 1 to 14)
Trial: 22276821
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m² on day 1) + Gemcitabine (1000 mg/m² on days 1 and 8)
Trial: 22276821
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg for the first six cycles of chemotherapy)
Trial: 20858863
Drug: Creatinine (>90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine (>90 μmol/L)
Trial: 15848695
Drug: Thymoglobulin, sirolimus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin, sirolimus, reduced-dose cyclosporine, and corticosteroids
Trial: 12088164
Drug: Ziprasidone, 80-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone, 80-160 mg/day (N = 148)
Trial: 12088164
Drug: Haloperidol, 5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol, 5-15 mg/day (N = 153)
Trial: 2221488
Drug: Quazolast, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazolast, 400 mg bid orally
Trial: 74533
Drug: Concentrated dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated dietary fibre from bran (20 g/day)
Trial: 74533
Drug: Concentrated dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated dietary fibre from cabbage (20 g/day)
Trial: 74533
Drug: Concentrated dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated dietary fibre from carrot (20 g/day)
Trial: 74533
Drug: Concentrated dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated dietary fibre from apple (20 g/day)
Trial: 74533
Drug: Concentrated dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concentrated dietary fibre from guar gum (20 g/day)
Trial: 30457436
Drug: HDC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC vaccine (HDCV)
Trial: 30457436
Drug: Hamster kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hamster kidney cell vaccine
Trial: 21338892
Drug: Random laboratory
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random laboratory drug testing program (PDT)
Trial: 19149760
Drug: Chemotherapy or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy or EGFR inhibitors
Trial: 19149760
Drug: New EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New EGFR inhibitors
Trial: 15202617
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (specifics not provided)
Trial: 11229673
Drug: Intratumoral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral injection of HSV1716 (10^3 plaque-forming units)
Trial: 25638740
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 1.2mcg/kg/hour (high dose)
Trial: 25638740
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) 0.4mcg/kg/hour (low dose)
Trial: 19138934
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (smokers with oral tissue methylation)
Trial: 19138934
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (smokers without oral tissue methylation)
Trial: 19138934
Drug: Baseline methylation
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline methylation for p16 in oral tissue
Trial: 19138934
Drug: Baseline methylation
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline methylation for FHIT in oral tissue
Trial: 19138934
Drug: Baseline methylation
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline methylation for both p16 and FHIT in oral tissue
Trial: 19138934
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of methylation patterns between oral and bronchial tissues
Trial: 15258349
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg/d)
Trial: 1543449
Drug: Aspirin (650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (650 mg/d)
Trial: 11795342
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/day) for up to 8 years
Trial: 28694471
Drug: 2% doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% doxycycline solution
Trial: 25867446
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy guided self-help (CBTgsh)
Trial: 25867446
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy guided self-help (CBTgsh) and Interpersonal psychotherapy (IPT)
Trial: 20196109
Drug: DBT‐AF (appetite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT‐AF (appetite focused dialectical behavior therapy)
Trial: 19708562
Drug: Transcranial electrotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial electrotherapy using a TRANSAIR‐02 apparatus (combined with traditional treatment)
Trial: 14571451
Drug: Fluoride gel
RxNorm normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride gel treatment (EF group)
Trial: 14571451
Drug: Fluoride gel
RxNorm normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride gel treatment followed by argon laser irradiation (EFL group)
Trial: 14571451
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (E group)
Trial: 10594469
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg once daily
Trial: 10594469
Drug: Doxazosin standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin standard (1 mg day-1 titrated to higher dose)
Trial: 10594469
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS 4 mg and 8 mg
Trial: 10594469
Drug: Doxazosin GITS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin GITS once daily for 7 days
Trial: 6762670
Drug: Manipulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation of the cervical spine with an amnesic dose of diazepam
Trial: 6421359
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (10 micrograms) given at 0, 1, and 2 months of age
Trial: 6421359
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (10 micrograms) given at 3, 4, and 5 months of age
Trial: 27276421
Drug: Deferiprone (DFP)
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone (DFP) 33 mg kg(‐1) single oral dose
Trial: 27276421
Drug: Deferiprone 3‐O‐glucuronide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone 3‐O‐glucuronide (DFP‐G)
Trial: 23383461
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (true acupuncture needles), treated once every other day for 12 sessions
Trial: 23383461
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (true acupuncture needles)
Trial: 20655809
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch) for 30 minutes
Trial: 20655809
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch) for 60 minutes
Trial: 20655809
Drug: NGX-4010 (8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGX-4010 (8% capsaicin patch) for 90 minutes
Trial: 20655809
Drug: Pooled control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled control group (0.04% capsaicin patch)
Trial: 18841250
Drug: Difluoromethylornithine (DFMO)
RxNorm normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Difluoromethylornithine (DFMO) 500 mg and sulindac 150 mg once daily
Trial: 15901456
Drug: GIII series
RxNorm normalized name: triclosan
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIII series sequential media
Trial: 12525796
Drug: PYC (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PYC (200 mg/day)
Trial: 2870876
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg loprazolam
Trial: 6142463
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg nitrazepam
Trial: 12022239
Drug: Irbesartan (AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (AT1 receptor antagonist)
Trial: 12022239
Drug: Atenolol (beta1-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta1-adrenergic receptor blocker)
Trial: 7491227
Drug: Oxandrolone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.1 mg/kg daily for 1 year)
Trial: 1780618
Drug: PGE2 administration
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 administration for cervical maturation
Trial: 7039244
Drug: Continuous heparin
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous heparin treatment
Trial: 7039244
Drug: Intermittent heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent heparin treatment
Trial: 7039244
Drug: Both continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both continuous and intermittent heparin treatment
Trial: 31661346
Drug: Integrated Psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated Psychological Therapy (IPT)
Trial: 30346226
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (TAU)